Ranolazine is an effective second-line treatment option for chronic stable angina that improves myocardial efficiency without significantly affecting heart rate or blood pressure.
Ranolazine is a novel anti-anginal agent indicated for the management of chronic stable angina, particularly in patients who remain symptomatic despite conventional therapy. Unlike traditional anti-anginal drugs, ranolazine exerts its therapeutic effect without significantly affecting heart rate or blood pressure, primarily through inhibition of the late inward sodium current in cardiac myocytes. This review presents a concise overview of angina and anti-anginal therapy, followed by a detailed discussion of ranolazine including its chemical structure, mechanism of action, therapeutic applications, and regulatory history. Furthermore, a comprehensive literature review of reported analytical methods for the estimation of ranolazine is provided, covering UV-visible spectrophotometry, derivative spectrophotometry, reverse phase high-performance liquid chromatography (RP-HPLC), liquid–liquid extraction HPLC methods, and high-performance thin-layer chromatography (HPTLC). The compiled analytical data highlight the wide range of techniques employed for quantitative determination of ranolazine in bulk drug, pharmaceutical dosage forms, and biological matrices. This review serves as a useful reference for researchers and analysts involved in pharmaceutical analysis and quality control of ranolazine.
Darshangiri B. Gowsami1*, Dr. Khushbu Patel2, Mrs. Shushila R. Prajapati3, Dr. C. N. Patel4 (Sun,) conducted a review in Patients with chronic stable angina inadequately controlled with conventional therapy. Ranolazine vs. Conventional anti-anginal therapy or placebo was evaluated on Efficacy of ranolazine in management of chronic stable angina. Ranolazine is an effective second-line treatment option for chronic stable angina that improves myocardial efficiency without significantly affecting heart rate or blood pressure.